Long-Acting Injectable Cabotegravir for HIV Pre-Exposure Prophylaxis (PrEP): Promising Results from HPTN 083
Treatment Action Group (TAG) welcomes the news that long-acting injectable cabotegravir (CAB LA, from ViiV Healthcare) demonstrated a high level of efficacy for preventing HIV infection in cisgender men and transgender women who have sex with men in the HIV Prevention Trials Network (HPTN) 083 trial.